替吉奥联合奥沙利铂治疗晚期食管癌近期疗效观察  

S-1 capsule combined with oxaliplatin for patients with advanced esophageal cancer

作　　者：许杨[1] 庞东生[1] 汪济东[1] 

机构地区：[1]中国人民解放军海军安庆医院肿瘤科,安徽安庆246003

出　　处：《实用肿瘤杂志》2014年第4期368-370,共3页Journal of Practical Oncology

摘　　要：目的观察替吉奥联合奥沙利铂治疗晚期食管癌的近期疗效及不良反应。方法 30例晚期食管癌均接受化疗,替吉奥80 mg/(m2·d),分2次,餐后口服,d1-14;奥沙利铂130 mg/m2,d1,静脉滴注>3小时,21天为1周期,2周期后行胸腹部CT及消化道钡餐造影或胃镜评价疗效,并评价不良反应。结果 30例患者均可评价疗效,完全缓解(CR)0例,部分缓解(PR)12例,病情稳定(SD)8例,病情进展(PD)10例,有效率(CR+PR)为40.0%,临床获益率(CR+PR+SD)为66.7%。中位疾病进展时间5月,1年生存率63.3%。主要不良反应为血液学毒性、消化道反应、肝功能损伤、皮疹、神经毒性等。结论替吉奥联合奥沙利铂治疗晚期食管癌疗效较好,不良反应可耐受。Objective To evaluate the efficacy and toxicity of S-1 capsule（ tegafur-gimeracil-oteracil） combined with oxaliplatin in treatment of advanced esophageal cancer. Methods Thirty patients with advanced esophageal cancer received S-1 plus oxaliplatin chemotherapy regimen： S-1 capsule 80 mg/（ m2·d）,bid,d1-14; oxaliplatin 130 mg/m2,d1,i. v.〉 3 h; 21 d as one cycle. After two cycles of chemotherapy,the efficacy and toxicity were evaluated. Results All30 cases were evaluable. Overall response rate was 40. 0%,disease control rate was 66. 7%,the median time to progression was 5 months and one-year survival rate was 63. 3%. The major toxicities were hemotological toxicity,gastrointestinal reactions,liver dysfunction,rash and neurotoxicity. Conclusion S-1 capsule combined with oxaliplatin is effective and safe for patients with advanced esophageal cancer.

关 键 词：食管肿瘤 药物疗法 食管肿瘤 病理学 输注 静脉内 有机铂化合物 投药和剂量 抗肿瘤联合化疗方案 治疗应用 化学疗法 辅助 方法 治疗结果 

分 类 号：R735.1[医药卫生—肿瘤] R730.53[医药卫生—临床医学]